...
首页> 外文期刊>Chemweek's business daily >EVONIK TO DIVEST MAJORITY STAKE IN ITS ENERGY BUSINESS; EYES ISOPHORONE INVESTMENT
【24h】

EVONIK TO DIVEST MAJORITY STAKE IN ITS ENERGY BUSINESS; EYES ISOPHORONE INVESTMENT

机译:EVONIK将减少其在能源业务中的利益眼睛异黄酮投资

获取原文
获取原文并翻译 | 示例
           

摘要

The Rhein-Ruhr consortium, a grouping of seven municipal utility companies in Germany's Ruhr region, has agreed to acquire a 51% stake in Evonik Steag, the energy subsidiary of Evonik Industries, for european dollar 649 million. The deal is expected to close at the end of the first quarter of 2011, subject to all necessary approvals. Evonik has also agreed to sell the remaining 49% of Evonik Steag to the consortium for european dollar 594 million after a retention period of up to five years. Evonik announced one year ago that it planned to split off its real estate business and Evonik Steag, as part of a strategy to focus on chemicals.The company said it would seek investors in Evonik Steag, which would be managed as an independent subsidiary. Selling the 51% interest in Evonik Steag "is an important step in our repositioning as a specialty chemicals group," Evonik chairman Klaus Engel says. "The proceeds of the transaction will be used for a value-enhancing expansion of the chemicals business and to improve Evonik's finan- cial profile," he says. Chemicals account for about 80% of Evonik's sales and Ebitda, prior to the divestment of the Evonik Steag shares, Engel says. Separately, Evonik says it intends to construct a plant that will make isophorone and isophorone diamine at a yet-to- be-decided location, most likely in Asia. The board of the Evonik Degussa subsidiary has approved the project plan and production is scheduled to start in 2013. "We're particularly looking at attractive investment climates in Southeast Asia and China, and will take these into consideration when taking the final decision," says Gerd Brand, head of Evonik's crosslinkers business line. Evonik currently has isophorone production at Herne and Marl, Germany; Antwerp; and Mobile, AL. "The market for isophorone and its derivatives is growing steadily and proved to be robust even during the economic crisis," says Evonik chairman Klaus Engel. The planned investment would create a framework for a possible expansion of Evonik's product range in isophorone chemistry, the company says. Evonik says it is the only company to produce the entire isophorone line, consisting of isophorone, isophorone diamine, isophorone diisocyanate, and derivatives. They are used as components in products with applicationsthat include industrial flooring, artificial leather, paints and coatings, and high-performance composites.
机译:莱茵-鲁尔财团由德国鲁尔地区的七个市政公用事业公司组成,已同意以6.49亿美元的价格收购赢创工业能源子公司赢创Steag 51%的股份。这项交易预计将在2011年第一季度末完成,但须获得所有必要的批准。赢创还同意在长达五年的保留期后,以5.94亿欧元的价格将赢创Steag的剩余49%股份出售给该财团。赢创在一年前宣布计划将其房地产业务和赢创Steag分开,作为专注于化学品战略的一部分,该公司表示将寻求赢创Steag的投资者,后者将作为独立子公司进行管理。赢创董事长克劳斯·恩格尔说,出售赢创Steag 51%的股份“​​是我们重新定位为特种化学品集团的重要一步。”他说:“交易的收益将用于增值化学品业务,并改善赢创的财务状况。”恩格尔说,在剥离赢创Steag股份之前,化工产品约占赢创EBITDA的80%。赢创另外表示,它打算在尚未确定的地点(最有可能在亚洲)建造一家将生产异佛尔酮和异佛尔酮二胺的工厂。赢创德固赛(Evonik Degussa)子公司董事会已批准了该项目计划,并计划于2013年开始生产。“我们特别关注东南亚和中国的有吸引力的投资环境,并将在做出最终决定时将这些因素考虑在内。”赢创的交联剂业务部主管Gerd Brand说。赢创目前在德国黑尔讷和马尔生产异佛尔酮;安特卫普和AL。赢创董事长克劳斯·恩格尔说:“异佛尔酮及其衍生物的市场正在稳定增长,即使在经济危机期间也被证明是强劲的。”该公司表示,计划中的投资将为赢创可能在异佛尔酮化学领域扩大产品范围创造一个框架。赢创表示,这是唯一一家生产整个异佛尔酮产品线的公司,该产品线包括异佛尔酮,异佛尔酮二胺,异佛尔酮二异氰酸酯及其衍生物。它们用作产品的组件,其应用包括工业地板,人造革,油漆和涂料以及高性能复合材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号